DLA
GSK icon

Douglas Lane & Associates’s GSK GSK Stock Holding History

Douglas Lane & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.6M Sell
946,636
-62,765
-6% -$3.32M 0.67% 63
2026
Q1 		$55.7M Sell
1,009,401
-35,389
-3% -$1.92M 0.8% 50
2025
Q4 		$51.2M Sell
1,044,790
-76,109
-7% -$3.55M 0.7% 56
2025
Q3 		$48.4M Sell
1,120,899
-196,210
-15% -$7.66M 0.67% 62
2025
Q2 		$50.6M Sell
1,317,109
-204,417
-13% -$7.81M 0.73% 55
2025
Q1 		$58.9M Sell
1,521,526
-106,978
-7% -$3.92M 0.87% 46
2024
Q4 		$55.1M Sell
1,628,504
-544,979
-25% -$19.6M 0.78% 48
2024
Q3 		$88.9M Sell
2,173,483
-34,927
-2% -$1.43M 1.22% 27
2024
Q2 		$85M Sell
2,208,410
-12,141
-0.5% -$511K 1.21% 24
2024
Q1 		$95.2M Sell
2,220,551
-15,613
-0.7% -$644K 1.35% 21
2023
Q4 		$82.9M Sell
2,236,164
-75,727
-3% -$2.72M 1.28% 26
2023
Q3 		$83.8M Buy
2,311,891
+87,789
+4% +$3.12M 1.41% 21
2023
Q2 		$79.3M Buy
2,224,102
+61,812
+3% +$2.22M 1.28% 28
2023
Q1 		$76.9M Buy
2,162,290
+108,193
+5% +$3.79M 1.28% 29
2022
Q4 		$72.2M Buy
2,054,097
+464,538
+29% +$15.5M 1.21% 35
2022
Q3 		$46.8M Buy
1,589,559
+119,131
+8% +$4.52M 0.86% 46
2022
Q2 		$80M Buy
1,470,428
+35,005
+2% +$1.93M 1.36% 24
2022
Q1 		$78.2M Buy
1,435,423
+41,625
+3% +$2.26M 1.1% 33
2021
Q4 		$76.8M Buy
1,393,798
+75,167
+6% +$3.91M 1.02% 33
2021
Q3 		$63M Buy
1,318,631
+133,435
+11% +$6.7M 0.9% 42
2021
Q2 		$59M Buy
1,185,196
+109,979
+10% +$5.28M 0.83% 47
2021
Q1 		$48M Buy
1,075,217
+141,889
+15% +$6.44M 0.74% 56
2020
Q4 		$42.9M Buy
933,328
+62,750
+7% +$2.88M 0.72% 53
2020
Q3 		$41M Buy
870,578
+113,801
+15% +$5.7M 0.81% 47
2020
Q2 		$38.6M Buy
756,777
+65,572
+9% +$3.36M 0.83% 46
2020
Q1 		$32.7M Buy
691,205
+94,720
+16% +$5.05M 0.86% 45
2019
Q4 		$35M Buy
596,485
+270,855
+83% +$15.1M 0.65% 61
2019
Q3 		$17.4M Buy
+325,630
New +$16.8M 0.35% 85

Other funds holding GSK

MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Douglas Lane & Associates's GSK Position: Q2 2026 in Review

Douglas Lane & Associates reduced its GSK (GSK) stake by 6.2% in Q2 2026, selling an estimated $3.32M and leaving 946,636 shares worth $49.6M. The position accounts for 0.67% of the portfolio, ranked #63.

Douglas Lane & Associates first reported a position in GSK in Q3 2019 and has held it in 28 quarters since. The position peaked at $95.2M in Q1 2024. 406 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Douglas Lane & Associates held 946,636 shares of GSK worth $49.6M as of Q2 2026.
  • Douglas Lane & Associates sold 62,765 GSK shares in Q2 2026, an estimated $3.32M.
  • GSK made up 0.67% of Douglas Lane & Associates's portfolio in Q2 2026, its #63 holding.
  • Douglas Lane & Associates first reported a position in GSK in Q3 2019 and has held it in 28 quarters since.
  • Douglas Lane & Associates's GSK position peaked at $95.2M in Q1 2024.
  • 406 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Douglas Lane & Associates's 13F filing for Q2 2026, filed 14 Jul 2026.